The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia


AKSU S., ŞAHİN F., Uz B., YAVUZ S., Atay H., Kelkitli E., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, ss.8-14, 2012 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 22 Konu: 1
  • Basım Tarihi: 2012
  • Doi Numarası: 10.4999/uhod.12004
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Sayfa Sayısı: ss.8-14

Özet

We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.